PL3388420T3 - Związki chinolinowe, sposób ich wytwarzania i ich zastosowanie jako leku stanowiącego inhibitor transportera anionu kwasu moczowego - Google Patents

Związki chinolinowe, sposób ich wytwarzania i ich zastosowanie jako leku stanowiącego inhibitor transportera anionu kwasu moczowego

Info

Publication number
PL3388420T3
PL3388420T3 PL16872373.2T PL16872373T PL3388420T3 PL 3388420 T3 PL3388420 T3 PL 3388420T3 PL 16872373 T PL16872373 T PL 16872373T PL 3388420 T3 PL3388420 T3 PL 3388420T3
Authority
PL
Poland
Prior art keywords
preparation
quinoline compounds
transporter inhibitor
inhibitor drug
urate transporter
Prior art date
Application number
PL16872373.2T
Other languages
English (en)
Inventor
Lei Fan
Wu Du
Xinghai Li
Yuanwei Chen
Kexin Xu
Ke Chen
Shaohua Zhang
Tongchuan LUO
Original Assignee
Hinova Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hinova Pharmaceuticals Inc. filed Critical Hinova Pharmaceuticals Inc.
Publication of PL3388420T3 publication Critical patent/PL3388420T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
PL16872373.2T 2015-12-07 2016-12-06 Związki chinolinowe, sposób ich wytwarzania i ich zastosowanie jako leku stanowiącego inhibitor transportera anionu kwasu moczowego PL3388420T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510896887 2015-12-07
PCT/CN2016/108688 WO2017097182A1 (zh) 2015-12-07 2016-12-06 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途

Publications (1)

Publication Number Publication Date
PL3388420T3 true PL3388420T3 (pl) 2022-12-05

Family

ID=59013742

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16872373.2T PL3388420T3 (pl) 2015-12-07 2016-12-06 Związki chinolinowe, sposób ich wytwarzania i ich zastosowanie jako leku stanowiącego inhibitor transportera anionu kwasu moczowego

Country Status (15)

Country Link
US (1) US10450274B2 (pl)
EP (1) EP3388420B1 (pl)
JP (1) JP6752888B2 (pl)
CN (2) CN106831569B (pl)
AU (1) AU2016368240B2 (pl)
BR (1) BR112018011390B1 (pl)
CA (1) CA3007783C (pl)
DK (1) DK3388420T3 (pl)
ES (1) ES2926781T3 (pl)
HU (1) HUE059672T2 (pl)
PL (1) PL3388420T3 (pl)
PT (1) PT3388420T (pl)
RU (1) RU2715229C2 (pl)
TW (1) TWI744264B (pl)
WO (1) WO2017097182A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110452168B (zh) * 2018-05-07 2022-03-15 中国医学科学院药物研究所 N-苯基-n-喹啉羧酸类化合物及其制法和药物用途
CN110467571B (zh) * 2018-05-11 2021-02-26 江苏恒瑞医药股份有限公司 一种制备环烷基甲酸类衍生物或其可药用盐的方法
CN108853112B (zh) * 2018-06-13 2021-02-02 四川理工学院 化合物或其在药学上可接受的盐在制备治疗痛风、高尿酸血症药物中的应用
WO2020088641A1 (zh) * 2018-11-02 2020-05-07 江苏恒瑞医药股份有限公司 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
US11926632B2 (en) 2020-06-22 2024-03-12 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
CN113559074B (zh) * 2020-06-28 2023-04-21 海创药业股份有限公司 一种喹啉类化合物缓释片及其制备方法
CN114315705B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与用途
CN114621136B (zh) * 2020-12-09 2023-11-07 江苏正大清江制药有限公司 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用
CN115385854B (zh) * 2021-05-19 2024-04-09 江苏正大清江制药有限公司 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用
KR20240055886A (ko) * 2021-09-17 2024-04-29 하이노바 파마슈티컬스 인코포레이티드 퀴놀린계 화합물의 서방성 정제 및 그 제조 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096140A (en) * 1937-10-19 Unsymmetkical indigoid dyesttjffs
US2568037A (en) * 1947-10-24 1951-09-18 Sterling Drug Inc Tertiary-aminoalkyl esters and amides of 4-quinolylmercaptoalkanoic acids and their preparation
JP2000510870A (ja) * 1997-02-14 2000-08-22 バイエル・コーポレーシヨン Ｎｐｙ５受容体アンタゴニストとしてのアミド類
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
CN102481299B (zh) * 2009-02-12 2015-02-25 艾科尔公司 包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物
CA2781888C (en) * 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
JP2014503528A (ja) * 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
ES2668721T3 (es) * 2013-05-13 2018-05-21 Shanghai Hengrui Pharmaceutical Co. Ltd. Derivado de ácido de cicloalquilo, método de preparación y aplicación farmacéutica del mismo

Also Published As

Publication number Publication date
RU2715229C2 (ru) 2020-02-26
PT3388420T (pt) 2022-09-20
CA3007783C (en) 2021-06-08
JP6752888B2 (ja) 2020-09-09
RU2018120242A3 (pl) 2020-01-09
US20180362466A1 (en) 2018-12-20
ES2926781T3 (es) 2022-10-28
CN106831569A (zh) 2017-06-13
BR112018011390B1 (pt) 2024-01-09
RU2018120242A (ru) 2020-01-09
CN106831570A (zh) 2017-06-13
CA3007783A1 (en) 2017-06-15
US10450274B2 (en) 2019-10-22
CN106831569B (zh) 2020-07-17
EP3388420A1 (en) 2018-10-17
DK3388420T3 (da) 2022-09-26
BR112018011390A2 (pt) 2018-12-04
AU2016368240A1 (en) 2018-06-28
TWI744264B (zh) 2021-11-01
HUE059672T2 (hu) 2022-12-28
CN106831570B (zh) 2020-03-31
WO2017097182A1 (zh) 2017-06-15
EP3388420B1 (en) 2022-06-22
AU2016368240B2 (en) 2020-01-02
JP2019502673A (ja) 2019-01-31
TW201720797A (zh) 2017-06-16
EP3388420A4 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
HUE054964T2 (hu) Pirazol-heteroaril készítmény, az elõállítás módja és gyógyászati felhasználása
HUE059672T2 (hu) Kinolinvegyületek, eljárás azok elõállítására, és urát transzporter inhibitor gyógyzserként történõ alkalmazásuk
HK1255566A1 (zh) 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用
HK1231377A1 (zh) 包含喹啉衍生物或其鹽的藥物組合物及其製備方法
IL259711A (en) Methods for the preparation of protein kinase inhibitors and their medical use
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
EP3299369A4 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
IL250524B (en) Carboxylic acid compound, method for its preparation and use
EP3369734A4 (en) KINASEINHIBITOR AND METHOD OF PREPARATION AND PHARMACEUTICAL USE THEREOF
HK1244808A1 (zh) 苯並哌啶類衍生物、其製備方法及其在醫藥上的應用
EP3115361A4 (en) Heterocyclic compounds, and preparation method and use thereof
EP3231802A4 (en) Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof
EP3327014A4 (en) Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
EP3438105A4 (en) DIARYL-BETA-LACTAM COMPOUND AND METHOD OF MANUFACTURE AND PHARMACEUTICAL USE THEREOF
EP3181553A4 (en) Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
HK1256362A1 (zh) 共晶、其製造方法及含有共晶的藥物
EP3381919A4 (en) Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof
HK1246279A1 (zh) C14-位羥基酯化的雷公藤甲素氨基酸衍生物、及其製備方法和應用
EP3388433A4 (en) PHTHALAZINE DERIVATIVE AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3354648A4 (en) 4-SUBSTITUTED CUMARINE DERIVATIVE AND METHOD OF PREPARATION AND USE THEREOF
EP3243823A4 (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
EP3130340A4 (en) Isoacteoside derivative and preparation method and use thereof
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them